Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL — Stella

Home/Non-Hodgkin Lymphoma/

View on ClinicalTrials.gov

Recruiting

Back to Non-Hodgkin Lymphoma trials

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(1 site)

United States

New York Medical College, Valhalla, New York

Key details

Phase

Safety & dosing

Sponsor

New York Medical College

Collaborators

Roswell Park Cancer Institute

Enrollment target

~25 participants

Started

August 2015

Primary completion

December 2026

Age range

3 Years – 31 Years

Last updated August 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.